Open an account

BridgeBio Pharma

BBIO · NASDAQ

$67.55−$0.39 (−0.57%)TodayMarket closed ·
Prev close $67.94

About BBIO

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. The company is headquartered in Palo Alto, California and currently employs 834 full-time employees. The company went IPO on 2019-06-27. The company discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. The company also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

Employees
834
Headquarters
Palo Alto, California
Listed
Jun 27, 2019
Sector
Health Care
Industry
Biotechnology
Website
bridgebio.com

BBIO key statistics

Market cap
13.28B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.85M
Volume
1.90M
Open price
$68.28
High today
$69.00
Low today
$67.25
52 Week high
$93.42
52 Week low
$52.75

BridgeBio Pharma (BBIO) at a glance

As of Oct 20, 2026, BridgeBio Pharma (BBIO) shares are priced at $67.55, giving the company a market cap of 13.28B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $67.25 and $69.00. The current price is 0.4% above the day's low and 2.1% below its high.

Volume so far is 1.90M shares, below the average of 2.85M shares a day.

Over the past year BridgeBio Pharma has ranged from $52.75 to $93.42, and now sits 36% of the way up that range.

BridgeBio Pharma met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q2 FY26 it reported -$0.78 per share against an estimate of -$0.5951.

The average analyst price target is $111.25, 64.7% above the current price, from 22 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

91%of 22 analyst ratings say Buy
  • Buy90.9%
  • Hold9.1%
  • Sell0.0%
Price target · 22 analystsAvg $111.25
Low
$80.80
Now
$67.55
High
$164.85

BBIO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 6.6% on average.

  1. Q3 FY24: reported -$1.10 per share against an estimate of -$0.9981
  2. Q4 FY24: reported -$1.40 per share against an estimate of -$1.15
  3. Q1 FY25: reported -$0.88 per share against an estimate of -$0.9418
  4. Q2 FY25: reported -$0.95 per share against an estimate of -$0.8602
  5. Q3 FY25: reported -$0.95 per share against an estimate of -$0.9064
  6. Q4 FY25: reported -$1.00 per share against an estimate of -$0.757
  7. Q1 FY26: reported -$0.84 per share against an estimate of -$0.6921
  8. Q2 FY26: reported -$0.78 per share against an estimate of -$0.5951

BBIO news

  • Press releaseGlobe Newswire

    Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records

  • Press releasePRNewswire

    BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day

  • Press releaseGlobe Newswire

    BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

  • Vandana Singh

    BridgeBio Dwarfism Data Shows Broad Health Benefits Beyond Height Gain

  • Namrata Sen

    Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President

  • Press releaseGlobe Newswire

    BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates

  • Vandana Singh

    Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain

  • Press releaseGlobe Newswire

    International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma

Similar companies

Companies in the same industry as BridgeBio Pharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.